Beam Therapeutics (BEAM) Assets Average (2020 - 2026)

Beam Therapeutics (BEAM) has 7 years of Assets Average data on file, last reported at $1.5 billion in Q1 2026.

• On a quarterly basis, Assets Average rose 15.22% year-over-year to $1.5 billion in Q1 2026; TTM through Mar 2026 was $1.5 billion, a 15.22% increase from a year earlier, with the FY2025 full-year figure at $1.3 billion, up 0.84% from the prior year.
• Assets Average for Q1 2026 stood at $1.5 billion, up from $1.4 billion in the prior quarter.
• Over the last five years, Assets Average for BEAM reached as high as $1.5 billion in Q1 2026 and fell as low as $1.1 billion in Q4 2024.
• Historically, Assets Average has averaged $1.4 billion across 5 years, with a median of $1.4 billion in 2025.
• Across the five-year window, Assets Average surged 155.73% in 2022 and slipped 17.27% in 2024, its largest moves.
• Year by year, Assets Average stood at $1.3 billion in 2022, then rose by 2.17% to $1.4 billion in 2023, then declined by 17.27% to $1.1 billion in 2024, then gained by 22.73% to $1.4 billion in 2025, then advanced by 6.08% to $1.5 billion in 2026.
• Per Business Quant data, the three most recent Assets Average figures were $1.5 billion in Q1 2026, $1.4 billion in Q4 2025, and $1.4 billion in Q3 2025.